U.S. markets open in 4 hours 28 minutes
  • S&P Futures

    3,891.75
    +24.25 (+0.63%)
     
  • Dow Futures

    31,578.00
    +220.00 (+0.70%)
     
  • Nasdaq Futures

    13,146.50
    +91.25 (+0.70%)
     
  • Russell 2000 Futures

    2,256.20
    +27.10 (+1.22%)
     
  • Crude Oil

    60.68
    +0.93 (+1.56%)
     
  • Gold

    1,727.30
    -6.30 (-0.36%)
     
  • Silver

    26.82
    -0.06 (-0.24%)
     
  • EUR/USD

    1.2102
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.4150
    0.0000 (0.00%)
     
  • Vix

    22.76
    -0.59 (-2.53%)
     
  • GBP/USD

    1.3985
    +0.0029 (+0.21%)
     
  • USD/JPY

    106.8900
    +0.1800 (+0.17%)
     
  • BTC-USD

    51,392.98
    +2,444.24 (+4.99%)
     
  • CMC Crypto 200

    1,028.33
    +40.24 (+4.07%)
     
  • FTSE 100

    6,691.08
    +77.33 (+1.17%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Cabaletta Bio
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m. ET.

A live webcast of the presentation will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com